http://venturebeat.com/2007/05/31/jazz-pharma-takes-it-on-the-chin-raises-less-than-expected-108m-in-ipo/ News About Tech, Money and Innovation Mon, 23 Nov 2009 21:25:39 +0000 http://wordpress.org/?v=2.8.5 hourly 1 http://venturebeat.com/2007/05/31/jazz-pharma-takes-it-on-the-chin-raises-less-than-expected-108m-in-ipo/comment-page-1/#comment-862366 Cyndi Feigenbaum Thu, 11 Sep 2008 14:03:15 +0000 http://venturebeat.com/2007/05/31/jazz-pharma-takes-it-on-the-chin-raises-less-than-expected-108m-in-ipo/#comment-862366 Xyrem is a drug with a great future and many uses. It was misused by children so lets get it straight. It is a neurotransmiter and if our body stopped producing it we would all be dead. Xyrem is a drug with a great future and many uses. It was misused by children so lets get it straight. It is a neurotransmiter and if our body stopped producing it we would all be dead.

]]> http://venturebeat.com/2007/05/31/jazz-pharma-takes-it-on-the-chin-raises-less-than-expected-108m-in-ipo/comment-page-1/#comment-585062 VentureBeat » Life sciences briefing: Thursday, Oct. 18, 2007 Thu, 18 Oct 2007 18:07:48 +0000 http://venturebeat.com/2007/05/31/jazz-pharma-takes-it-on-the-chin-raises-less-than-expected-108m-in-ipo/#comment-585062 [...] that only two U.S. pharma/biotechs — the specialty pharmas Jazz Pharmaceuticals (covered here) and Eurand — have managed to pull in more than $100 million with IPOs this year. Of course, [...] [...] that only two U.S. pharma/biotechs — the specialty pharmas Jazz Pharmaceuticals (covered here) and Eurand — have managed to pull in more than $100 million with IPOs this year. Of course, [...]

]]> http://venturebeat.com/2007/05/31/jazz-pharma-takes-it-on-the-chin-raises-less-than-expected-108m-in-ipo/comment-page-1/#comment-401604 VentureBeat » MAP Pharma charts course for $86M IPO Fri, 10 Aug 2007 23:45:25 +0000 http://venturebeat.com/2007/05/31/jazz-pharma-takes-it-on-the-chin-raises-less-than-expected-108m-in-ipo/#comment-401604 [...] which have been markedly unfriendly for pharmas and biotechs in recent months. The much-anticipated Jazz Pharmaceuticals IPO, for instance, was marked down twice, and even then the company’s shares traded down [...] [...] which have been markedly unfriendly for pharmas and biotechs in recent months. The much-anticipated Jazz Pharmaceuticals IPO, for instance, was marked down twice, and even then the company’s shares traded down [...]

]]>